Drugs for Alzheimer's disease

There is no cure for Alzheimer's disease, but medication can help manage it. The main drugs now in use are symptomatic therapies - they ease symptoms without addressing the underlying cause. These include cholinesterase inhibitors and memantine. A more recent entry, lecanemab, may help slow the disease's progression. Here is how these medications work.
Cholinesterase inhibitors
One way Alzheimer's damages the brain is by lowering levels of acetylcholine, a chemical messenger involved in alertness, memory, and thinking. Cholinesterase inhibitors raise the amount of acetylcholine available to nerve cells by blocking its breakdown in the brain.
Three drugs in this class are FDA-approved: donepezil (Aricept), galantamine (generic), and rivastigmine (Exelon). They can be prescribed at any stage of Alzheimer's, mild to severe, and are taken daily as pills; rivastigmine also comes as a skin patch.
These drugs can turn back the clock on memory loss, but only modestly. "They can restore your memory to like it was six to 12 months before, but the drugs can't slow the disease's progression," says a specialist in cognitive neurology. "And you have to keep taking the drug to maintain that advantage." Most people feel the effects within one to two months.
Most patients do well on any of the cholinesterase inhibitors, the specialist adds, but because there is the longest track record with donepezil, it is usually tried first, with galantamine generally the second choice. The drugs are covered by Medicare and well tolerated by most people, though common side effects include upset stomach, nausea, vivid dreams, and loose stools.
Because rivastigmine comes as a patch, it is often used for people who cannot tolerate the pills. And people with certain cardiac arrhythmias should avoid this drug class altogether, since it can slow the heart rate.
Memantine
Another symptomatic drug, approved for moderate-to-severe Alzheimer's, is memantine (Namenda). It works by modulating glutamate and dopamine, two chemicals that carry messages between nerve cells and are broadly involved in brain functions including memory.
Doctors typically prescribe memantine when a person with Alzheimer's starts having trouble with activities of daily living such as dressing and bathing. "It is prescribed to help slow down the progression of symptoms, which could enable some people to maintain some daily functions a little longer than they would without the medication," the specialist says.
The drug is taken as a pill or liquid once or twice a day, and improvement can take three months or longer to appear. Common side effects include dizziness, headache, drowsiness, confusion, and agitation.
Lecanemab
This newer drug, FDA-approved in January 2023, works differently: it aims to slow the progression of the disease itself.
Lecanemab (Leqembi) is an immunotherapy that targets the protein beta-amyloid, slowing the buildup of amyloid plaques in the brain. Plaques make it hard for brain cells to communicate, impairing memory and other mental functions. "The drug doesn't stop new plaque from forming, but slows the speed at which it can accumulate," the specialist explains.
It works only in early-stage Alzheimer's - people with mild cognitive impairment or mild dementia. "These are individuals who have trouble with thinking and memory and struggle with completing complicated tasks like paying bills and grocery shopping - but don't have problems with daily living," he says.
A major study published in January 2023 followed 1,795 people with MRI-confirmed amyloid plaques and mild memory problems. Compared with those on an inactive treatment, people who took lecanemab for 18 months showed a slower rate of cognitive decline on cognitive tests and less amyloid in their brains.
Lecanemab is given every other week as an hourlong infusion; whether it must be taken indefinitely is not yet known. Its main risks are brain swelling and brain bleeding, so people on powerful blood thinners are advised against it. Candidates are also advised to get genetic testing for an Alzheimer's risk-factor gene: people with two copies of the gene have between three and 10 times the likelihood of side effects.




